Replies to post #213085 on Biotech Values

[DewDiligence]

Re: RVNC phase-3 data reporting

The transcript excerpt you posted is erroneous, and there has been no change in RVNC’s data-reporting schedule for the phase-3 program in glabellar lines.

Please listen to the webcast starting at the 7:30 time point (http://edge.media-server.com/m/p/c222cid2 ).

RVNC will report top-line efficacy and safety data from SAKURA-1 and SAKURA-2 in 4Q17, presumably in a single press release.

SAKURA-3, the open-label safety study for 2,000 patients, is still enrolling and will wrap up in late 2018 (https://www.clinicaltrials.gov/ct2/show/NCT03004248 ).

Slide #15 in RVNC’s latest slide set shows the above timeline (http://investors.revance.com/common/download/download.cfm?companyid=AMDA-2GNRV0&fileid=953583&filekey=52A8D2C5-7900-4F55-8595-1EA8C217BABE&filename=Revance_Company_Presentation_Update_8_10_17.pdf ).